Potentially new therapies in thyroid cancer

Textbook of Endocrine Surgery

Volumn , Issue , 2005, Pages 334-343

  Park, Jin Woo ^a   Duh, Quan Yang ^b   Clark, Orlo H ^b  

^a Chungbuk National University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250647100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0139-7.50039-9     Document Type: Chapter

References (141)

1. Learoyd DL, Messina M, Zedenius J, et al. Molecular genetics of thyroid tumors and surgical decision-making. World J Surg 2000, 24:923.
2. Schmutzler C, Köhrle J Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000, 10:393.
3. Napoli JL Biochemical pathways of retinoid transport, metabolism, and signal transduction. Clin Immunol Immunopathol 1996, 80:S52.
4. Rowe A, receptors Retinoid X Int J Biochem Cell Biol 1997, 29:275.
5. Lopez-Boado YS, Tolivia J, Lopez-Otin C Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells:. J Biol Chem 1994, 269:26871.
6. Dahiya R, Park HD, Cusick J, et al. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13- cis-retinoic acid. Int J Cancer 1994, 59:126.
7. Sueoka N, Lee HY, Walsh GL, et al. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all- trans retinoic acid in human bronchial epithelial cells. Cancer Res 1999, 59:3838.
8. Van Herle AJ, Agatep ML, Padua DN, et al. Effects of 13- cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990, 71:755.
9. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998, 39:1903.
10. Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997, 240:832.
11. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998, 22:569.
12. Ferrandina G, Filippini P, Ferlini C, et al. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol Res 2001, 12:429.
13. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001, 7:3047.
14. Vasse M, Thibout D, Paysant J, et al. Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules. Br J Cancer 2001, 84:802.
15. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J Clin Oncol 1999, 17:984.
16. Myers CE Differentiating agents and nontoxic therapies. Urol Clin North Am 1999, 26:341.
17. Lea MA, Tulsyan N Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995, 15:879.
18. Han S, Wada RK, Sidell N Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res 2001, 61:3998.
19. Samid D, Wells M, Greene ME, et al. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: Binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 2000, 6:933.
20. Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996, 2:379.
21. Cosentini E, Haberl I, Pertschy P, et al. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. lnt J Oncol 2001, 19:1069.
22. Di Benedetto M, Kourbali Y, Starzec A, et al. Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice. Br J Cancer 2001, 85:917.
23. Witzig TE, Timm M, Stenson M, et al. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 2000, 6:681.
24. Kebebew E, Wong MG, Siperstein AE, et al. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 1999, 84:2840.
25. Eigelberger MS, Wong MG, Duh QY, et al. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery 2001, 130:931.
26. Corton JC, Anderson SP, Stauber A Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000, 40:491.
27. Roberts-Thomson SJ Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment. Immunol Cell Biol 2000, 78:436.
28. Davies GF, Khandelwal RL, Roesler WJ Troglitazone induces expression of PPARgamma in liver. Mol Cell Biol Res Commun 1999, 2:202.
29. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000, 278:704.
30. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806.
31. Guan YF, Zhang YH, Breyer RM, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999, 1:330.
32. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998, 58:3344.
33. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998, 4:1046.
34. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000, 83:1394.
35. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000, 270:400.
36. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgammal fusion in oncogene human thyroid carcinoma. Science 2000, 289:1357.
37. Ohta K, Endo T, Haraguchi K, et al. Ligands tor peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:2170.
38. Park JW, Hyun WC, Wong MG et al Troglitazone inhibits growth and down-regulates dedifferentiation nTarker cd97 in thyroid cancer cell lines. Submitted to Thyroid.
39. Loidl P Histone acetylation: Facts and questions. Chromosoma 1994, 103:441.
40. Mahlknecht U, Hoelzer D Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000, 6:623.
41. Weidle UH, Grossmann A Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000, 20:1471.
42. Jung M Inhibitors of histone deacetylasc as new anticancer agents. Curr Med Chem 2001, 8:1505.
43. Minister PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61:8492.
44. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718.
45. Greenberg VL, Williams JM, Cogswell JP, et al. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 2001, 11:315.
46. Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:3430.
47. Zarnegar R, Brunaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002, 132:984.
48. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103.
49. Kogai T, Hershman JM, Motomura K, et al. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells. Endocrinology 2001, 142:3369.
50. Kitazono M, Chuman Y, Aikou T, et al. Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:834.
51. Jossart GH, Epstein HD, Shaver JK, et al. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 1996, 81:3498.
52. Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 2000, 85:302.
53. Fagin JA, Tang SH, Zeki K, et al. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 1996, 56:765.
54. Kim SB, Ahn IM, Park HJ, et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck 2001, 23:223.
55. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000, 85:4081.
56. Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 1998, 83:3668.
57. Nagayama Y, Shigematsu K, Namba H, et al. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res 2000, 20:2723.
58. +/I symporter gene expression. Mol Endocrinol 1998, 12:727.
59. Mascia A, De Felice M, Lipardi C, et al. Transfection of TTF-1 gene induces thyroglobulin gene expression in undifferentiated FRT cells. Biochim Biophys Acta 1997, 1354:171.
60. van der Kallen CJ, Spierings DC, Thijssen JH, et al. Disrupted co-ordination of Pax-8 and thyroid transcription factor-1 gene expression in a dedifferentiated rat thyroid tumour cell line derived from FRTL-5. J Endocrinol 1996, 150:377.
61. Chun YS, Saji M, Zeiger MA Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines. Surgery 1998, 124:1100.
62. Castro MR, Bergert ER, Goellner JR, et al. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: Correlation with radioiodine uptake. J Clin Endocrinol Metab 2001, 86:5627.
63. Russo D, Bulotta S, Bruno R, et al. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 2001, 145:591.
64. Mian C, Lacroix L, Alzieu L, et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001, 11:825.
65. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001, 8:1524.
66. Nakamoto Y, Saga T, Misaki T, et al. Establishment and characterization of a breast cancer cell line expressing NaVr symporters for radioiodide concentrator gene therapy. J Nucl Med 2000, 41:1898.
67. Haberkorn U Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp Clin Endocrinol Diabetes 2001, 109:60.
68. Smit JW, Schroder-van der Elst JP, Karperien M, et al. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp Clin Endocrinol Diabetes 2001, 109:52.
69. Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001, 8:612.
70. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1999, 84:499.
71. Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res 2001, 61:3640.
72. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999, 17:12.
73. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94:902.
74. Kotchetkov R, Groschel B, Gmeiner WH, et al. Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitro. Anticancer Res 2000, 20:2915.
75. Ringel MD, Greenberg M, Chen X, et al. Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells. Thyroid 2000, 10:865.
76. Dadan J, Wolczynski S, Sawicki B, et al. Preliminary evaluation of influence of gemcitabine (Gemzar) on proliferation and neuroendocrine activity of human TT cell line: Immunocytochemical investigations. Folia Histochem Cytobiol 2001, 39:187.
77. Voigt W, Bulankin A, Muller T, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000, 6:2087.
78. Delord JP, Raymond E, Chaouche M, et al. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol 2000, 11:73.
79. Hartl FU Molecular chaperones in cellular protein folding. Nature 1996, 381:571.
80. Helmbreeht K, Zeise E, Reusing L Chaperones in cell cycle regulation and mitogenic signal transduction: A review. Cell Prolif 2000, 33:341.
81. Ferrarini M, Heltai S, Zocchi MR, Rugarli C Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992, 51:613.
82. Magnuson NS, Beck T, Vahidi H, et al. The Raf-1 serine/threonine protein kinase. Semin Cancer Biol 1994, 5:247.
83. Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996, 271:4974.
84. Blagosklonny MV, Toretsky J, Neckers L Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995, 11:933.
85. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995, 36:305.
86. Park JW, Yeh MW, Wong MG, et al. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, downregulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 2003, 88:3346.
87. Munster PN, Tong W, Schwartz L et al Phase I pharmacologic syudy of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in patients (Pts) with advanced solid malignancies [Abstract]. American Society of Clinical Oncology, Annual Meeting, San Francisco, May 2001.
88. Zhang R, DeGroot LJ Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy. Thyroid 2000, 10:313.
89. Klatzmann D, Cherin P, Bensimon G, et al. A phase I/Il dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998, 9:2585.
90. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998, 9:2595.
91. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999, 17:2180.
92. Nishihara E, Nagayama Y, Mawatari F, et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 1997, 138:4577.
93. Braiden V, Nagayama Y, Iitaka M, et al. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 1998, 139:3996.
94. Zhang R, Straus FH, DeGroot LJ Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 2001, 11:115.
95. Nagayama Y, Nishihara E, Iitaka M, et al. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 1999, 59:3049.
96. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992, 10:275.
97. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3:409.
98. Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther 2002, 9:64.
99. Zhang R, Straus FH, DeGroot LJ Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: Dissemination and cytotoxicity studies in a rat tumor model. Endocrinology 1999, 140:2152.
100. Zhang R, Baunoch D, DeGroot LJ Genetic immunotherapy for medullary thyroid carcinoma: Destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid 1998, 8:1137.
101. Soler MN, Milhaud G, Lekmine F, et al. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol Immunother 1999, 48:91.
102. Aasland R, Lillehaug JR, Male R, et al. Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB. Br J Cancer 1988, 57:358.
103. Akslen LA, Varhaug JE Oncoproteins and tumor progression in papillary thyroid carcinoma: Presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995, 76:1643.
104. Haugen DR, Akslen LA, Varhaug JE, et al. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 1992, 65:832.
105. Auguste LJ, Masood S, Westerbancl A, et al. Oncogene expression in follicular neoplasms of the thyroid. Am J Surg 1992, 164:592.
106. Haugen DR, Akslen LA, Varhaug JE, et al. Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. lnt J Cancer 1993, 55:37.
107. Holting T, Siperstein AE, Clark OH, et al. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 1995, 132:229.
108. Gabler B, Aicher T, Heiss P, et al. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 1997, 17:3157.
109. Mincione G, Cirafici AM, Lazzareschi D, et al. Loss of thyrotropin regulation and transforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells. Cancer Res 1993, 53:5548.
110. Hudson LG, Santon JB, Glass CK, et al. Ligand-activated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression. Cell 1990, 62:1165.
111. de Bono JS, Rowinsky EK The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2002, 8:S19.
112. Herbst RS, Shin DM Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002, 94:1593.
113. Jackson C Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 2002, 11:295.
114. Zucker S, Cao J, Chen WT Critical appraisal of the use of matrix met-alloproteinase inhibitors in cancer treatment. Oncogene 2000, 19:6642.
115. Kraiem Z, Korem S Matrix metalloproteinases and the thyroid. Thyroid 2000, 10:1061.
116. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999, 59:467.
117. Hofmann A, Laue S, Rost AK, et al. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 1998, 8:203.
118. Rooprai HK, Rucklidge GJ, Panou C, et al. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 2000, 82:52.
119. O-Charoenrat P, Modjtahedi H, Rhys-Evans P, et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000, 60:1121.
120. Zielke A, Hoffmann S, Plaul U, et al. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion. Exp Clin Endocrinol Diabetes 1999, 107:361.
121. Korem S, Resnick MB, Kraiem Z Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. J Clin Endocrinol Metab 1999, 84:3322.
122. Packman KS, Demeure MJ, Doffek KM, et al. increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells. Surgery 1995, 118:1011.
123. Jiang Y, Goldberg ID, Shi YE Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245.
124. Yoshizaki T, Sato H, Furukawa M Recent advances in the regulation of matrix metalloproteinase 2 activation: From basic research to clinical implication [Review]. Oncol Rep 2002, 9:607.
125. Bonomi P Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002, 29(1 Suppl 4):78.
126. Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. lnt J Cancer 1999, 80:764.
127. Lokeshwar BL, Selzer MG, Zhu BQ, et al. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. lnt J Cancer 2002, 98:297.
128. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AlDS-related Kaposi's sarcoma: A phase 1 AIDS malignancy consortium study. J Clin Oncol 2002, 20:153.
129. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001, 19:584.
130. Yeh MW, Rougier JP, Park JW et al Invasion by thyroid cancer cells is regulated by signaling through the EGF receptor and effected by activated gelatinases. Submitted to Cancer Res.
131. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997, 82:3741.
132. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: Strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999, 161:41.
133. Fenton C, Patel A, Dinauer C, et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000, 10:349.
134. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001, 129:552.
135. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:656.
136. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (P1GF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11:1569.
137. Belletti B, Ferraro P, Arra C, et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 1999, 18:4860.
138. Soh EY, Sobhi SA, Wong MG, et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996, 120:944.
139. Tuttle RM, Fleisher M, Francis GL, et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002, 87:1737.
140. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000, 128:1059.
141. Xu G, Pan J, Martin C, Yeung SC Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:1769.